III期表皮生长因子受体（EGFR）突变的非小细胞肺癌放化疗后使用奥希替尼的疗效 - Suppr

Suppr

超能文献

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

作者信息

Banna Giuseppe Luigi, Addeo Alfredo

机构信息

University of Portsmouth, Portsmouth, United Kingdom

Geneva University Hospital, Geneva, Switzerland.

出版信息

N Engl J Med. 2024 Oct 24;391(16):1555. doi: 10.1056/NEJMc2411471.

DOI:10.1056/NEJMc2411471

PMID:39442049

Abstract

摘要

相似文献

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

N Engl J Med. 2024 Oct 24;391(16):1555. doi: 10.1056/NEJMc2411471.

Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC.

N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2.

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of + NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III -Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).

Lung Cancer (Auckl). 2025 Apr 25;16:51-55. doi: 10.2147/LCTT.S520833. eCollection 2025.

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

J Thorac Oncol. 2021 Jun;16(6):1030-1041. doi: 10.1016/j.jtho.2021.01.1628. Epub 2021 Feb 12.

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.

Ann Oncol. 2024 Dec;35(12):1116-1125. doi: 10.1016/j.annonc.2024.08.2243. Epub 2024 Sep 16.

A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.

Future Oncol. 2021 Dec 1;17(35):4827-4835. doi: 10.2217/fon-2021-0752. Epub 2021 Nov 1.

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.

J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24.

A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC.

Future Oncol. 2025 Apr;21(8):903-915. doi: 10.1080/14796694.2025.2463880. Epub 2025 Feb 24.

A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.

Future Oncol. 2025 Apr;21(8):917-928. doi: 10.1080/14796694.2025.2463318. Epub 2025 Mar 6.

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.

BMC Pulm Med. 2024 Oct 16;24(1):517. doi: 10.1186/s12890-024-03336-8.

引用本文的文献

Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: systematic review and network meta-analysis.

BMJ. 2025 Sep 2;390:e082834. doi: 10.1136/bmj-2024-082834.

Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study).

J Thorac Dis. 2025 May 30;17(5):2947-2957. doi: 10.21037/jtd-2024-2266. Epub 2025 May 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验